Deep Brain Stimulation (DBS)
Deep Brain Stimulation (DBS) is an effective, long-term therapy for the management of Parkinson’s disease and other movement disorders. It is a specialised therapy and involves an expert multidisciplinary team including neurosurgeons, neurologists, psychiatry, and a DBS nurse specialist.
DBS therapy uses surgically implanted electrodes and a neurostimulator to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain, thereby targeting specific patient symptoms.
A clinician programmer is used to adjust the stimulation to best control the individual's symptoms while minimising side effects. A patient programming device gives patients some control over their settings, within physician-prescribed limits.
Sydney Adventist Hospital is the fourth DBS centre in NSW and one of only two centres with a DBS nurse specialist.
Apomorphine Therapy
Apomorphine is a potent dopamine agonist that works by mimicking the action of dopamine, making it a treatment option for Parkinson’s disease (PD). It comes in two forms, intermittent injections or a continuous infusion therapy.
Apomorphine Pen
Apomorphine injections are prescribed for people that have early motor fluctuations. It is administered via an injection and helps reduce motor fluctuations when oral Parkinson Disease medications wear off.
The Apomorphine pen will begin to work within 5 to 10 minutes after administration and effects generally wear off after 40 minutes. The usual frequency of dosing is between 3-5 time per day depending on the response. Apomorphine injections can be added to the usual PD regime.
Apomorphine infusion
Unlike the pen, apomorphine infusion slowly releases the drug via a pump subcutaneously which bypasses the digestive system. In most cases, the infusion is started in the morning and removed at bedtime. Therapy will allow for a dose reduction in oral levodopa by about 30-50% while other dopamine agonists will usually be ceased.
Duodopa Therapy
Duodopa is a gel form of levodopa that delivers duodopa directly into the jejunum or small intestine via a feeding tube. It is PBS covered and has been available in Australia since 2014.
Duodopa replaces all oral medications and delivers a continuous infusion for a maximum of 16 hours a day. It is commenced in the morning when the individual wakes up, and is disconnected at bedtime. In rare cases, the individual may be on a 24hr infusion for example, when they have severe nocturnal akinesia.
Duodopa is highly efficacious for motor symptoms and increases on time substantially. It is well tolerated once patients overcome the initial post operative period.